ClinicalTrials.gg
CompletedNCT04626505RESCUE-2Updated May 6, 2026Results posted

Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition in Japan.

A Phase 2 interventional study of Ziltivekimab and Placebo (ziltivekimab) in Chronic Kidney Disease, Inflammation and Cardiovascular Risk, sponsored by Novo Nordisk A/S. Completed at 1 site in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2026-05-06.

Sponsored by Novo Nordisk A/S · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies in Renal Insufficiency, Chronic by Novo Nordisk A/S — 5 open to participants now, 6 under way, 1 of them phase 3. Renal Insufficiency, Chronic · Novo Nordisk A/S.

Enrollment
15th of 18
36 · median 128
Started
2020
the only one that year
Phase 2
5 of 29
1 open now
Registered
10th of 29
by date

Among the 29 studies in Renal Insufficiency, Chronic by Novo Nordisk A/S, this one is the 15th largest by enrollment of the 18 interventional ones that give a count, is the only one that started in 2020, is one of 5 in phase 2, and was the 10th registered.

Renal Insufficiency, Chronic

3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

5 of the 29 studies in Renal Insufficiency, Chronic by Novo Nordisk A/S are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 244 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 44 take children under 18; 80 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Renal Insufficiency, Chronic by Novo Nordisk A/S, or all of them as a file.
02

Study summary

The purpose of this research study is to compare the safety and effectiveness of 2 different doses of a study drug called ziltivekimab to placebo (an inactive substance) in reducing inflammation and improving some of the bad effects of inflammation on heart disease. Participants will be randomly (by chance) assigned to receive either ziltivekimab or placebo. The chance that participants will be assigned into one of the three study arms of ziltivekimab (either 15 mg or 30 mg) or placebo is the same (approximately 33%). This is a double-blind study, which means neither participants nor the study doctor will know which group the participants are in. In case of an emergency, however, the study doctor can get this information. The study drug will be injected under the skin once every 4 weeks. In this study participants will receive 3 injections of study drug. The total study duration for each participant will be approximately 6 months.

03

Conditions studied

  • Chronic Kidney Disease
  • Inflammation
  • Cardiovascular Risk
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age equal to or above 20 years at the time of signing the Form
  • Stage 3 to 5 non-dialysis-dependent chronic kidney disease (NDD-CKD), ie, estimated above 10 and below 60 mL/min/1.73 m\^2 using the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) creatinine equation
  • Serum hs-CRP level equal to or above 2.0 mg/L measured during the screening period. Note: Targeting patients with a history of advanced stage CKD, atherosclerotic cardiovascular disease, anemia, diabetic retinopathy, obesity, or elevated , and diabetes for screening will help increase the chances of identifying patients with hs-CRP equal to or above2.0 mg/L 4. The patient agrees to comply with
  • The patient agrees to comply with the and reproduction restrictions of the study as follows:

    1. Women of must be using a method of contraception that is "highly effective" (ie, less than 1% failure rate) for at least 3 months following the last dose of study drug;
    2. women must have had no menstrual bleeding for at least 1 year before initial dosing and either be over the age of 60 years or have an elevated plasma follicle stimulating hormone level (ie, above 40 mIU/mL) at screening;
    3. Women of childbearing potential must have a documented negative serum pregnancy test result at screening; and
    4. All male patients, from the day of dosing until the final study visit, unless surgically sterile, must be willing to use a condom with a partner (male patients with partners of childbearing potential must be willing to use 2 effective methods of birth control, 1 should be condom with spermicide) to prevent pregnancy and drug exposure of a partner, and refrain from donating sperm or fathering a child; and
  • The patient must be willing and able to provide informed consent and abide all study requirements and restrictions.

Exclusion criteria

Exclusion Criteria:

Patients who meet any of the following criteria will be excluded from participation in the study:

Laboratory values

  • below 2.0 × 10\^9/L during screening;
  • count below 120 × 10\^9/L during screening;
  • Spot urine protein-creatinine ratio above 4000 mg/g (4.0 g/g) during screening;
  • or aspartate aminotransferase above 2.5 × during screening;
  • Positive testing for tuberculosis during screening. blood testing (eg, QuantiFERON) is preferred, but a purified protein derivative (PPD) skin test read within 48 to 72 hours by a qualified healthcare professional may also be performed. If a patient is PPD positive but QuantiFERON negative, the patient is eligible;
  • Evidence of (HIV)-1 or HIV-2 infection by serology measured during screening;
  • or C by serology (eg, hepatitis B surface antigen or antibody positive) measured during screening;

Medical conditions or diseases

  • Expected to require blood transfusion within 12 weeks post-randomization;
  • Thromboembolic event within 12 weeks prior to randomization;
  • Clinical evidence or suspicion of active infection;
  • History of peptic ulcer disease or gastrointestinal ulceration in the 12 months prior to randomization;
  • History of active diverticulitis in the 12 months prior to randomization;
  • History of inflammatory bowel disease that has been clinically active during the 12 months prior to randomization;
  • Uncontrolled hypertension (defined as an average systolic blood pressure above 160 mmHg or an average diastolic blood pressure above 100 mmHg) during screening. Patients may be re-evaluated within 2 weeks, at the discretion of the Principal Investigator, for this criterion if antihypertensive therapy has been started or increased as a result of initial screening blood pressure being above these limits;
  • Planned coronary revascularization (percutaneous coronary intervention or coronary artery bypass grafting) or any other major surgical procedure during the time frame of the study;
  • Major cardiac surgical, non-cardiac surgical, or major endoscopic procedure within the past 6 months prior to randomization;
  • Prior gastric bypass surgery;
  • History of (NYHA) Class IV congestive heart failure within 12 weeks prior to randomization;
  • Diagnosis of within 1 year prior to randomization with the exception of successfully treated nonmetastatic basal cell or squamous cell carcinomas of the skin and/or local carcinoma in situ of the cervix;
  • History of bone marrow or solid organ transplant or anticipated to receive an organ transplant during the time frame of the study;
  • Known allergy to the study drug or any of its ingredients;

Prior or current medications

  • Received an drug within 30 days prior to screening;
  • Received a product within 14 days of study drug administration or expect to receive live vaccine during the treatment period;
  • Expected to receive any investigational drug or any of the exclusionary drugs during the treatment period or safety follow-Up period;
  • Chronic use of systemic drugs during the screening period or anticipated use of such drugs any time during the study. Note: Use of otic, ophthalmic, inhaled, and topical or local corticosteroid injections are not exclusionary. Oral prednisone up to 5 mg per day (or equivalent) is permitted if the dose has been stable for at least 4 weeks prior to Screening and no dose changes are planned during study participation. Short-term use of oral steroids for treatment of rash or asthma exacerbation is allowed;
  • Use of systemic antibiotics, systemic antivirals, or systemic antifungals during the screening period. Note: "Systemic" is defined as oral or intravenous drugs that are absorbed into the circulation;
  • Requirement of an indwelling catheter of any type; 28. Use of hypoxia-inducible factor (HIF) stabilizers or erythropoiesis-stimulating agents (ESA) within 6 weeks of randomization or during the treatment period;

General exclusions

  • Currently breastfeeding; or
  • Any condition that could interfere with, or for which the treatment might interfere with, the conduct of the study or interpretation of the study results, or that would in the opinion of the Investigator increase the risk of participating in the study.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Ziltivekimab 15 mg

    Participants will receive ziltivekimab 15 mg for 12 weeks.

    Drug: Ziltivekimab

  • Experimental
    Ziltivekimab 30 mg

    Participants will receive ziltivekimab 30 mg for 12 weeks.

    Drug: Ziltivekimab

  • Placebo comparator
    Placebo (ziltivekimab)

    Participants will receive placebo (ziltivekimab) for 12 weeks.

    Drug: Placebo (ziltivekimab)

Interventions

  • Administered subcutaneously (s.c., under skin) once every 4 weeks for 12 weeks

  • DrugPlacebo (ziltivekimab)

    Administered s.c. once every 4 weeks for 12 weeks

06

What researchers measure

Primary outcomes

  1. Percent Change in High-sensitivity C-reactive Protein (Hs-CRP) Levels From Baseline (Average of All Hs-CRP Values Prior to the Administration of Study Drug) to the End of Treatment (Average of Week 10 and Week 12)

    Percent change in hs-CRP levels from baseline (average of the hs-CRP value prior to the administration of study drug) to the end of treatment (average of Week 10 and Week 12) is presented. Baseline was defined as the average of all hs-CRP values prior to the first administration of study drug at day 1 and end of treatment was defined as the average of hs-CRP values at week 10 and week 12.

    Time frame: Baseline (day 1), end of treatment (average of week 10 and week 12)

Secondary outcomes

  1. Number of Treatment-emergent Adverse Events (TEAEs)

    An adverse event (AE) was any undesirable event or any untoward medical occurrence that occurred in a participant during the course of the study or the protocol-defined time after study termination, whether or not that event was considered study drug-related. A TEAE was defined as an AE that initiated or worsened on or after the date of first dose of study drug up to the end of the safety follow-up period (week 20). Number of TEAEs from randomization (day 1) to week 20 are presented.

    Time frame: From randomization (Day 1) to week 20

  2. Number of Serious Adverse Events (SAEs)

    An AE was any undesirable event or any untoward medical occurrence that occurred in a participant during the course of the study or the protocol-defined time after study termination, whether or not that event was considered study drug-related. An SAE was defined as any untoward medical occurrence that at any dose results in death, or is life-threatening, or requires inpatient hospitalization or causes prolongation of existing hospitalization results in persistent or significant disability/incapacity, or may have caused a congenital anomaly/birth defect, or requires intervention to prevent permanent impairment or damage. ). Number of SAEs from randomization (day 1) to week 20 are presented.

    Time frame: From randomization (Day 1) to week 20

  3. Number of Participants With Vital Signs Parameters Exceeding Pre-defined Criteria

    Number of participants with vital signs parameters (including systolic blood pressure, heart rate and respiratory rate) exceeding pre-defined criteria are presented. The pre-defined criteria were: 1) systolic blood pressure: greater than (\>25) millimeters of mercury (mmHg) increase or decrease from baseline and \>160 mmHg; 2) heart rate: \>100 beats per minute; 3)respiratory rate: \>24 breaths per minute.

    Time frame: From randomization (Day 1) to week 20

  4. Change in Electrocardiogram (ECG)

    The ECG was assessed by the investigator at baseline (Day 1) and week 20 and categorised as abnormal clinically significant, abnormal not clinically significant, indeterminate, normal, not evaluable and unknown. Number of participants in each ECG category at baseline and week 20 are presented.

    Time frame: Baseline (Day 1), Week 20

  5. Change From Baseline in Alanine Aminotransferase, Alkaline Phosphatase, Amylase, Aspartate Aminotransferase, Creatine Kinase, Gamma Glutamyl Transferase, Lactate Dehydrogenase (LDH) and Lipase Pancreatic

    Change from baseline (Day 1) to week 20 in alanine aminotransferase, alkaline phosphatase, amylase, aspartate aminotransferase, creatine kinase, gamma glutamyl transferase, LDH and lipase pancreatic is presented.

    Time frame: Baseline (Day 1), Week 20

  6. Change From Baseline in Bicarbonate, Chloride, Potassium and Sodium

    Change from baseline (Day 1) to Week 20 in bicarbonate, chloride, potassium and sodium is presented.

    Time frame: Baseline (Day 1), Week 20

  7. Change From Baseline in Bilirubin, Calcium, Creatinine, Direct Bilirubin, Glucose, Phosphate, Urate, Urea Nitrogen

    Change from baseline (Day 1) to week 20 in bilirubin, calcium, creatinine, direct bilirubin, glucose, phosphate, urate and urea nitrogen is presented.

    Time frame: Baseline (Day 1), Week 20

  8. Change From Baseline in Glomerular Filtration Rate

    Change from baseline (Day 1) to week 20 in glomerular filtration rate is presented. Glomerular filtration rate was calculated by CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration)creatinine equation.

    Time frame: Baseline (Day 1), Week 20

  9. Change From Baseline in Protein

    Change from baseline (Day 1) to week 20 in protein is presented.

    Time frame: Baseline (Day 1), Week 20

  10. Change From Baseline in Eosinophils, Leukocyctes, Lymphocytes, Monocytes, Neutrophils and Platelets

    Change from baseline (Day 1) to week 20 in eosinophils, leukocyctes, lymphocytes, monocytes, neutrophils and platelets is presented.

    Time frame: Baseline (Day 1), Week 20

  11. Change From Baseline in Eosinophil/Leukocytes

    Change from baseline (Day 1) to week 20 in eosinophil/leukocytes is presented.

    Time frame: Baseline (Day 1), Week 20

  12. Change From Baseline in Erythrocyte Mean Corpuscular Volume

    Change from baseline (Day 1) to week 20 in erythrocyte mean corpuscular volume is presented.

    Time frame: Baseline (Day 1), Week 20

  13. Change From Baseline in Erythrocytes

    Change from baseline (Day 1) to week 20 in erythrocytes is presented.

    Time frame: Baseline (Day 1), Week 20

  14. Change From Baseline in Erythrocyte Distribution Width

    Change from baseline (Day 1) to week 20 in erythrocyte distribution width (ery. distribution width) is presented.

    Time frame: Baseline (Day 1), Week 20

  15. Change From Baseline in Hematocrit

    Change from baseline (Day 1) to week 20 in hematocrit is presented.

    Time frame: Baseline (Day 1), Week 20

  16. Change From Baseline in Lymphocytes/Leukocytes

    Change from baseline (Day 1) to week 20 in lymphocytes/leukocytes is presented.

    Time frame: Baseline (Day 1), Week 20

  17. Change From Baseline in Monocytes/Leukocytes

    Change from baseline (Day 1) to week 20 in monocytes/leukocytes is presented.

    Time frame: Baseline (Day 1), Week 20

  18. Change From Baseline in Neutrophils/Leukocytes

    Change from baseline (Day 1) to week 20 in neutrophils/leukocytes is presented.

    Time frame: Baseline (Day 1), Week 20

  19. Change From Baseline in Reticulocytes/Erythrocytes

    Change from baseline (Day 1) to week 20 in reticulocytes/erythrocytes is presented.

    Time frame: Baseline (Day 1), Week 20

  20. Change From Baseline in Protein Creatinine Ratio

    Change from baseline (Day 1) to week 12 in protein creatinine ratio is presented.

    Time frame: Baseline (Day 1), Week 12

  21. Change From Baseline in Specific Gravity of Urine

    Change from baseline (Day 1) to week 12 in specific gravity of urine is presented.

    Time frame: Baseline (Day 1), Week 12

  22. Change From Baseline in Spot Urine Albumin, Spot Urine Creatinine, Spot Urine Protein and Urobilinogen

    Change from baseline (Day 1) to week 12 in spot urine albumin, spot urine creatinine, spot urine protein and urobilinogen is presented.

    Time frame: Baseline (Day 1), Week 12

  23. Change From Baseline in Urine pH

    Change from baseline (Day 1) to week 12 in urine pH is presented.

    Time frame: Baseline (Day 1), Week 12

  24. Percentage of Participants With Adverse Events (AEs) Leading to Discontinuation of Study Drug

    Percentage of participants with AEs leading to discontinuation of study drug is presented.

    Time frame: From randomization (Day 1) to week 20

  25. Number of Treatment Emergent Adverse Events of Special Interest (AESIs)

    AESIs included serious infection, Common Terminology Criteria for Adverse Events (CTCAE) Grade greater than or equal to (\>=) 3 injection-related reactions, gastrointestinal perforations, CTCAE Grade \>=3 anaphylaxis that occurred at any time, even if considered unrelated to the study drug, neutrophil less than (\<) 500/mm\^3 (CTCAE Grade 4) or neutrophil \<1000/mm\^3 (CTCAE Grade 3) with evidence of concurrent infection, thrombocytopenia (platelet count \<50,000/mm\^3 \[CTCAE Grade 3\]) or platelet count \<75,000/mm\^3 (CTCAE Grade 2) with evidence of concurrent major bleeding and malignancies. Number of treatment emergent adverse events of special interest (AESIs) is presented.

    Time frame: From randomization (Day 1) to week 20

  26. Number of Participants With Antidrug Antibodies (ADAs) to Ziltivekimab

    Number of participants with ADAs to Ziltivekimab is presented. Data presented is partcipants who had at least 1 positive antibody sample (treatment-boosted or treatment-induced) at any time after their first Ziltivekimab administration.

    Time frame: From randomization (Day 1) to week 20

07

Results

Posted May 6, 2026

Participant flow

The trial was conducted in Japan and included 12 sites that were initiated, 11 sites that screened study participants, and 10 sites that enrolled study participants.

Participant flow — Overall Study
MilestonePlaceboZiltivekimab 15 mgZiltivekimab 30 mg
Started131112
Treated121112
Intent-to-treat (itt) population131112
Safety population121112
Completed121112
Not completed100
Withdrew: Adverse event100

Outcome measures

PrimaryPercent Change in High-sensitivity C-reactive Protein (Hs-CRP) Levels From Baseline (Average of All Hs-CRP Values Prior to the Administration of Study Drug) to the End of Treatment (Average of Week 10 and Week 12)

Percent change in hs-CRP levels from baseline (average of the hs-CRP value prior to the administration of study drug) to the end of treatment (average of Week 10 and Week 12) is presented. Baseline was defined as the average of all hs-CRP values prior to the first administration of study drug at day 1 and end of treatment was defined as the average of hs-CRP values at week 10 and week 12.

Time frame:
Baseline (day 1), end of treatment (average of week 10 and week 12)
Reported as:
Median · Percent change
Percent Change in High-sensitivity C-reactive Protein (Hs-CRP) Levels From Baseline (Average of All Hs-CRP Values Prior to the Administration of Study Drug) to the End of Treatment (Average of Week 10 and Week 12)
Percent changePlaceboZiltivekimab 15 mgZiltivekimab 30 mg
Percent Change in High-sensitivity C-reactive Protein (Hs-CRP) Levels From Baseline (Average of All Hs-CRP Values Prior to the Administration of Study Drug) to the End of Treatment (Average of Week 10 and Week 12)-27.01 (-46.71 to -3.83)-96.23 (-98.89 to -91.67)-93.41 (-96.59 to -88.34)
Statistical analysis
  • Placebo vs Ziltivekimab 15 mg · Hodges-Lehmann method · p = <0.0001 · Median of differences: -66.80 · 95% CI -87.79 to -44.84
  • Placebo vs Ziltivekimab 30 mg · Hodges-Lehmann method · p = 0.0002 · Median of differences: -62.44 · 95% CI -92.48 to -42.67
SecondaryNumber of Treatment-emergent Adverse Events (TEAEs)

An adverse event (AE) was any undesirable event or any untoward medical occurrence that occurred in a participant during the course of the study or the protocol-defined time after study termination, whether or not that event was considered study drug-related. A TEAE was defined as an AE that initiated or worsened on or after the date of first dose of study drug up to the end of the safety follow-up period (week 20). Number of TEAEs from randomization (day 1) to week 20 are presented.

Time frame:
From randomization (Day 1) to week 20
Reported as:
Number · Events
Number of Treatment-emergent Adverse Events (TEAEs)
EventsPlaceboZiltivekimab 15 mgZiltivekimab 30 mg
Number of Treatment-emergent Adverse Events (TEAEs)254116
SecondaryNumber of Serious Adverse Events (SAEs)

An AE was any undesirable event or any untoward medical occurrence that occurred in a participant during the course of the study or the protocol-defined time after study termination, whether or not that event was considered study drug-related. An SAE was defined as any untoward medical occurrence that at any dose results in death, or is life-threatening, or requires inpatient hospitalization or causes prolongation of existing hospitalization results in persistent or significant disability/incapacity, or may have caused a congenital anomaly/birth defect, or requires intervention to prevent permanent impairment or damage. ). Number of SAEs from randomization (day 1) to week 20 are presented.

Time frame:
From randomization (Day 1) to week 20
Reported as:
Number · Events
Number of Serious Adverse Events (SAEs)
EventsPlaceboZiltivekimab 15 mgZiltivekimab 30 mg
Number of Serious Adverse Events (SAEs)250
SecondaryNumber of Participants With Vital Signs Parameters Exceeding Pre-defined Criteria

Number of participants with vital signs parameters (including systolic blood pressure, heart rate and respiratory rate) exceeding pre-defined criteria are presented. The pre-defined criteria were: 1) systolic blood pressure: greater than (\>25) millimeters of mercury (mmHg) increase or decrease from baseline and \>160 mmHg; 2) heart rate: \>100 beats per minute; 3)respiratory rate: \>24 breaths per minute.

Time frame:
From randomization (Day 1) to week 20
Reported as:
Count of participants · Participants
Number of Participants With Vital Signs Parameters Exceeding Pre-defined Criteria
ParticipantsPlaceboZiltivekimab 15 mgZiltivekimab 30 mg
Systolic Blood Pressure: >25 mmHg increase or decrease from baseline534
Systolic Blood Pressure: >160 mmHg220
Heart Rate: >100 beats per minute120
Respiratory Rate: >24 breaths per minute000
SecondaryChange in Electrocardiogram (ECG)

The ECG was assessed by the investigator at baseline (Day 1) and week 20 and categorised as abnormal clinically significant, abnormal not clinically significant, indeterminate, normal, not evaluable and unknown. Number of participants in each ECG category at baseline and week 20 are presented.

Time frame:
Baseline (Day 1), Week 20
Reported as:
Count of participants · Participants
Change in Electrocardiogram (ECG)
ParticipantsPlaceboZiltivekimab 15 mgZiltivekimab 30 mg
Baseline (Day 1) — Abnormal, clinically significant021
Baseline (Day 1) — Abnormal, not clinically significant521
Baseline (Day 1) — Indeterminate000
Baseline (Day 1) — Normal7710
Baseline (Day 1) — Not evaluable000
Baseline (Day 1) — Unknown000
Week 20 — Abnormal, clinically significant110
Week 20 — Abnormal, not clinically significant532
Week 20 — Indeterminate000
Week 20 — Normal6710
Week 20 — Not evaluable000
Week 20 — Unknown000
SecondaryChange From Baseline in Alanine Aminotransferase, Alkaline Phosphatase, Amylase, Aspartate Aminotransferase, Creatine Kinase, Gamma Glutamyl Transferase, Lactate Dehydrogenase (LDH) and Lipase Pancreatic

Change from baseline (Day 1) to week 20 in alanine aminotransferase, alkaline phosphatase, amylase, aspartate aminotransferase, creatine kinase, gamma glutamyl transferase, LDH and lipase pancreatic is presented.

Time frame:
Baseline (Day 1), Week 20
Reported as:
Mean · Units per liter (U/L)
Change From Baseline in Alanine Aminotransferase, Alkaline Phosphatase, Amylase, Aspartate Aminotransferase, Creatine Kinase, Gamma Glutamyl Transferase, Lactate Dehydrogenase (LDH) and Lipase Pancreatic
Units per liter (U/L)PlaceboZiltivekimab 15 mgZiltivekimab 30 mg
Alanine Aminotransferase3.9 ± 13.9621.9 ± 34.615.6 ± 6.32
Alkaline Phosphatase0.4 ± 8.64-6.2 ± 18.14-12.4 ± 14.43
Amylase2.3 ± 13.376.7 ± 24.602.3 ± 18.19
Aspartate Aminotransferase-0.6 ± 9.8411.5 ± 14.170.7 ± 5.14
Creatine Kinase-36.2 ± 64.5719.9 ± 49.883.2 ± 38.00
Gamma Glutamyl Transferase0.4 ± 8.037.0 ± 11.375.8 ± 5.19
LDH2.5 ± 15.7119.5 ± 28.2415.9 ± 15.26
Lipase, Pancreatic15.9 ± 22.7427.9 ± 40.906.8 ± 41.20
SecondaryChange From Baseline in Bicarbonate, Chloride, Potassium and Sodium

Change from baseline (Day 1) to Week 20 in bicarbonate, chloride, potassium and sodium is presented.

Time frame:
Baseline (Day 1), Week 20
Reported as:
Mean · millimoles/L (mmol/L)
Change From Baseline in Bicarbonate, Chloride, Potassium and Sodium
millimoles/L (mmol/L)PlaceboZiltivekimab 15 mgZiltivekimab 30 mg
Bicarbonate-0.4 ± 3.73-1.7 ± 2.00-1.6 ± 2.68
Chloride0.8 ± 2.731.1 ± 2.211.3 ± 3.44
Potassium-0.38 ± 0.501-0.30 ± 0.6500.15 ± 0.284
Sodium0.7 ± 3.260.1 ± 2.470.0 ± 3.62
SecondaryChange From Baseline in Bilirubin, Calcium, Creatinine, Direct Bilirubin, Glucose, Phosphate, Urate, Urea Nitrogen

Change from baseline (Day 1) to week 20 in bilirubin, calcium, creatinine, direct bilirubin, glucose, phosphate, urate and urea nitrogen is presented.

Time frame:
Baseline (Day 1), Week 20
Reported as:
Mean · milligrams/deciliter (mg/dL)
Change From Baseline in Bilirubin, Calcium, Creatinine, Direct Bilirubin, Glucose, Phosphate, Urate, Urea Nitrogen
milligrams/deciliter (mg/dL)PlaceboZiltivekimab 15 mgZiltivekimab 30 mg
Bilirubin-0.122 ± 0.14970.158 ± 0.30730.030 ± 0.1566
Calcium-0.10 ± 0.429-0.17 ± 0.4130.08 ± 0.357
Creatinine0.176 ± 0.20870.188 ± 0.23680.210 ± 0.2895
Direct bilirubin-0.019 ± 0.01980.039 ± 0.09730.007 ± 0.0350
Glucose13.4 ± 45.5815.9 ± 21.641.7 ± 14.84
Phosphate-0.13 ± 0.4080.22 ± 0.3740.29 ± 0.287
Urate0.27 ± 1.1130.47 ± 1.0840.06 ± 0.611
Urea nitrogen3.3 ± 11.875.5 ± 8.236.3 ± 7.76
SecondaryChange From Baseline in Glomerular Filtration Rate

Change from baseline (Day 1) to week 20 in glomerular filtration rate is presented. Glomerular filtration rate was calculated by CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration)creatinine equation.

Time frame:
Baseline (Day 1), Week 20
Reported as:
Mean · mL/min/1.73m^2
Change From Baseline in Glomerular Filtration Rate
mL/min/1.73m^2PlaceboZiltivekimab 15 mgZiltivekimab 30 mg
Change From Baseline in Glomerular Filtration Rate-3.9 ± 5.90-3.5 ± 3.98-3.8 ± 3.02
SecondaryChange From Baseline in Protein

Change from baseline (Day 1) to week 20 in protein is presented.

Time frame:
Baseline (Day 1), Week 20
Reported as:
Mean · grams per deciliter (g/dL)
Change From Baseline in Protein
grams per deciliter (g/dL)PlaceboZiltivekimab 15 mgZiltivekimab 30 mg
Change From Baseline in Protein-0.02 ± 0.296-0.49 ± 0.617-0.02 ± 0.397
SecondaryChange From Baseline in Eosinophils, Leukocyctes, Lymphocytes, Monocytes, Neutrophils and Platelets

Change from baseline (Day 1) to week 20 in eosinophils, leukocyctes, lymphocytes, monocytes, neutrophils and platelets is presented.

Time frame:
Baseline (Day 1), Week 20
Reported as:
Mean · cells*10^9/L
Change From Baseline in Eosinophils, Leukocyctes, Lymphocytes, Monocytes, Neutrophils and Platelets
cells*10^9/LPlaceboZiltivekimab 15 mgZiltivekimab 30 mg
Eosinophils0.02 ± 0.083-0.05 ± 0.2880.08 ± 0.134
Leukocyctes0.44 ± 1.394-0.96 ± 1.615-0.73 ± 1.150
Lymphocytes0.288 ± 0.4916-0.047 ± 0.48400.066 ± 0.3977
Monocytes0.07 ± 0.2770.11 ± 0.1870.01 ± 0.183
Neutrophils0.062 ± 1.0308-0.974 ± 1.4803-0.900 ± 1.3441
Platelets-0.1 ± 46.23-35.7 ± 22.10-39.6 ± 35.56
SecondaryChange From Baseline in Eosinophil/Leukocytes

Change from baseline (Day 1) to week 20 in eosinophil/leukocytes is presented.

Time frame:
Baseline (Day 1), Week 20
Reported as:
Mean · Percentage of eosinophil/leukocytes
Change From Baseline in Eosinophil/Leukocytes
Percentage of eosinophil/leukocytesPlaceboZiltivekimab 15 mgZiltivekimab 30 mg
Change From Baseline in Eosinophil/Leukocytes0.24 ± 1.150-0.38 ± 3.8281.43 ± 1.966
SecondaryChange From Baseline in Erythrocyte Mean Corpuscular Volume

Change from baseline (Day 1) to week 20 in erythrocyte mean corpuscular volume is presented.

Time frame:
Baseline (Day 1), Week 20
Reported as:
Mean · femtoliters (fL)
Change From Baseline in Erythrocyte Mean Corpuscular Volume
femtoliters (fL)PlaceboZiltivekimab 15 mgZiltivekimab 30 mg
Change From Baseline in Erythrocyte Mean Corpuscular Volume0.18 ± 1.2072.44 ± 2.3682.92 ± 1.243
SecondaryChange From Baseline in Erythrocytes

Change from baseline (Day 1) to week 20 in erythrocytes is presented.

Time frame:
Baseline (Day 1), Week 20
Reported as:
Mean · cells x 10^12/L
Change From Baseline in Erythrocytes
cells x 10^12/LPlaceboZiltivekimab 15 mgZiltivekimab 30 mg
Change From Baseline in Erythrocytes-0.037 ± 0.2324-0.113 ± 0.2376-0.095 ± 0.1951
SecondaryChange From Baseline in Erythrocyte Distribution Width

Change from baseline (Day 1) to week 20 in erythrocyte distribution width (ery. distribution width) is presented.

Time frame:
Baseline (Day 1), Week 20
Reported as:
Mean · Percentage of ery. distribution width
Change From Baseline in Erythrocyte Distribution Width
Percentage of ery. distribution widthPlaceboZiltivekimab 15 mgZiltivekimab 30 mg
Change From Baseline in Erythrocyte Distribution Width0.42 ± 0.575-0.15 ± 0.7470.22 ± 0.658
SecondaryChange From Baseline in Hematocrit

Change from baseline (Day 1) to week 20 in hematocrit is presented.

Time frame:
Baseline (Day 1), Week 20
Reported as:
Mean · Percentage of hematocrit
Change From Baseline in Hematocrit
Percentage of hematocritPlaceboZiltivekimab 15 mgZiltivekimab 30 mg
Change From Baseline in Hematocrit-0.3 ± 2.22-0.1 ± 2.390.3 ± 2.05
SecondaryChange From Baseline in Lymphocytes/Leukocytes

Change from baseline (Day 1) to week 20 in lymphocytes/leukocytes is presented.

Time frame:
Baseline (Day 1), Week 20
Reported as:
Mean · Percentage of lymphocytes/leukocytes
Change From Baseline in Lymphocytes/Leukocytes
Percentage of lymphocytes/leukocytesPlaceboZiltivekimab 15 mgZiltivekimab 30 mg
Change From Baseline in Lymphocytes/Leukocytes3.07 ± 4.9801.76 ± 5.7104.62 ± 6.592
SecondaryChange From Baseline in Monocytes/Leukocytes

Change from baseline (Day 1) to week 20 in monocytes/leukocytes is presented.

Time frame:
Baseline (Day 1), Week 20
Reported as:
Mean · Percentage of monocytes/leukocytes
Change From Baseline in Monocytes/Leukocytes
Percentage of monocytes/leukocytesPlaceboZiltivekimab 15 mgZiltivekimab 30 mg
Change From Baseline in Monocytes/Leukocytes0.50 ± 3.1082.05 ± 2.5080.71 ± 2.831
SecondaryChange From Baseline in Neutrophils/Leukocytes

Change from baseline (Day 1) to week 20 in neutrophils/leukocytes is presented.

Time frame:
Baseline (Day 1), Week 20
Reported as:
Mean · Percentage of neutrophils/leukocytes
Change From Baseline in Neutrophils/Leukocytes
Percentage of neutrophils/leukocytesPlaceboZiltivekimab 15 mgZiltivekimab 30 mg
Change From Baseline in Neutrophils/Leukocytes-3.82 ± 6.593-3.32 ± 6.201-6.76 ± 9.278
SecondaryChange From Baseline in Reticulocytes/Erythrocytes

Change from baseline (Day 1) to week 20 in reticulocytes/erythrocytes is presented.

Time frame:
Baseline (Day 1), Week 20
Reported as:
Mean · Percentage of reticulocytes/erythrocytes
Change From Baseline in Reticulocytes/Erythrocytes
Percentage of reticulocytes/erythrocytesPlaceboZiltivekimab 15 mgZiltivekimab 30 mg
Change From Baseline in Reticulocytes/Erythrocytes0.11 ± 0.847-0.02 ± 0.389-0.04 ± 0.345
SecondaryChange From Baseline in Protein Creatinine Ratio

Change from baseline (Day 1) to week 12 in protein creatinine ratio is presented.

Time frame:
Baseline (Day 1), Week 12
Reported as:
Mean · grams per kilogram (g/kg)
Change From Baseline in Protein Creatinine Ratio
grams per kilogram (g/kg)PlaceboZiltivekimab 15 mgZiltivekimab 30 mg
Change From Baseline in Protein Creatinine Ratio412.3 ± 1783.53-148.9 ± 830.30-382.3 ± 729.52
SecondaryChange From Baseline in Specific Gravity of Urine

Change from baseline (Day 1) to week 12 in specific gravity of urine is presented.

Time frame:
Baseline (Day 1), Week 12
Reported as:
Mean · Ratio
Change From Baseline in Specific Gravity of Urine
RatioPlaceboZiltivekimab 15 mgZiltivekimab 30 mg
Change From Baseline in Specific Gravity of Urine0.0013 ± 0.00341-0.0009 ± 0.00263-0.0002 ± 0.00558
SecondaryChange From Baseline in Spot Urine Albumin, Spot Urine Creatinine, Spot Urine Protein and Urobilinogen

Change from baseline (Day 1) to week 12 in spot urine albumin, spot urine creatinine, spot urine protein and urobilinogen is presented.

Time frame:
Baseline (Day 1), Week 12
Reported as:
Mean · milligrams/deciliter (mg/dL)
Change From Baseline in Spot Urine Albumin, Spot Urine Creatinine, Spot Urine Protein and Urobilinogen
milligrams/deciliter (mg/dL)PlaceboZiltivekimab 15 mgZiltivekimab 30 mg
Spot urine albumin48.863 ± 132.020228.103 ± 94.3076-25.408 ± 36.3713
Spot urine creatinine7.48 ± 31.85410.95 ± 43.4900.34 ± 51.873
Spot urine protein51.7 ± 162.0638.8 ± 132.45-61.7 ± 92.90
Urobilinogen0.07 ± 0.2310.00 ± 0.000-0.13 ± 0.311
SecondaryChange From Baseline in Urine pH

Change from baseline (Day 1) to week 12 in urine pH is presented.

Time frame:
Baseline (Day 1), Week 12
Reported as:
Mean · pH
Change From Baseline in Urine pH
pHPlaceboZiltivekimab 15 mgZiltivekimab 30 mg
Change From Baseline in Urine pH0.21 ± 0.4500.23 ± 0.4670.13 ± 0.433
SecondaryPercentage of Participants With Adverse Events (AEs) Leading to Discontinuation of Study Drug

Percentage of participants with AEs leading to discontinuation of study drug is presented.

Time frame:
From randomization (Day 1) to week 20
Reported as:
Number · Percentage of participants
Percentage of Participants With Adverse Events (AEs) Leading to Discontinuation of Study Drug
Percentage of participantsPlaceboZiltivekimab 15 mgZiltivekimab 30 mg
Percentage of Participants With Adverse Events (AEs) Leading to Discontinuation of Study Drug000
SecondaryNumber of Treatment Emergent Adverse Events of Special Interest (AESIs)

AESIs included serious infection, Common Terminology Criteria for Adverse Events (CTCAE) Grade greater than or equal to (\>=) 3 injection-related reactions, gastrointestinal perforations, CTCAE Grade \>=3 anaphylaxis that occurred at any time, even if considered unrelated to the study drug, neutrophil less than (\<) 500/mm\^3 (CTCAE Grade 4) or neutrophil \<1000/mm\^3 (CTCAE Grade 3) with evidence of concurrent infection, thrombocytopenia (platelet count \<50,000/mm\^3 \[CTCAE Grade 3\]) or platelet count \<75,000/mm\^3 (CTCAE Grade 2) with evidence of concurrent major bleeding and malignancies. Number of treatment emergent adverse events of special interest (AESIs) is presented.

Time frame:
From randomization (Day 1) to week 20
Reported as:
Number · Events
Number of Treatment Emergent Adverse Events of Special Interest (AESIs)
EventsPlaceboZiltivekimab 15 mgZiltivekimab 30 mg
Number of Treatment Emergent Adverse Events of Special Interest (AESIs)110
SecondaryNumber of Participants With Antidrug Antibodies (ADAs) to Ziltivekimab

Number of participants with ADAs to Ziltivekimab is presented. Data presented is partcipants who had at least 1 positive antibody sample (treatment-boosted or treatment-induced) at any time after their first Ziltivekimab administration.

Time frame:
From randomization (Day 1) to week 20
Reported as:
Count of participants · Participants
Number of Participants With Antidrug Antibodies (ADAs) to Ziltivekimab
ParticipantsZiltivekimab 15 mgZiltivekimab 30 mg
Number of Participants With Antidrug Antibodies (ADAs) to Ziltivekimab00

Adverse events

Collected over From randomization (Day 1) to week 20. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/12 (0%)2/12 (16.7%)7/12 (58.3%)
Ziltivekimab 15 mg0/11 (0%)2/11 (18.2%)10/11 (90.9%)
Ziltivekimab 30 mg0/12 (0%)0/12 (0%)7/12 (58.3%)
Most frequent serious events
Most frequent serious events
EventPlaceboZiltivekimab 15 mgZiltivekimab 30 mg
Angina unstableCardiac disorders0/121/110/12
AppendicitisInfections and infestations0/121/110/12
Cardiac failure acuteCardiac disorders0/121/110/12
Chronic kidney diseaseRenal and urinary disorders0/121/110/12
Impaired healingGeneral disorders0/121/110/12
Corona virus infectionInfections and infestations1/120/110/12
Nephrotic syndromeRenal and urinary disorders1/120/110/12
Most frequent other events
Showing 10 of 57
Most frequent other events
EventPlaceboZiltivekimab 15 mgZiltivekimab 30 mg
Blood bilirubin increasedInvestigations0/122/110/12
EosinophiliaBlood and lymphatic system disorders0/122/110/12
PeriodontitisInfections and infestations2/121/111/12
Administration site pruritusGeneral disorders0/121/110/12
Atrial flutterCardiac disorders0/121/110/12
Blood pressure increasedInvestigations0/121/110/12
Cardiac failureCardiac disorders0/121/110/12
Cardiac failure chronicCardiac disorders0/121/110/12
ConjunctivitisInfections and infestations0/121/110/12
ConstipationGastrointestinal disorders0/121/111/12

Baseline characteristics

Intent-to-Treat (ITT) population included all randomized participants.

Age, Continuous
Age, Continuous(Years)PlaceboZiltivekimab 15 mgZiltivekimab 30 mgTotal
Mean63.6 ± 12.0166.2 ± 10.2661.4 ± 15.0963.7 ± 12.44
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboZiltivekimab 15 mgZiltivekimab 30 mgTotal
Female54312
Male87924
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboZiltivekimab 15 mgZiltivekimab 30 mgTotal
Hispanic or Latino0000
Not Hispanic or Latino13111236
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboZiltivekimab 15 mgZiltivekimab 30 mgTotal
American Indian or Alaska Native0000
Asian13111236
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White0000
More than one race0000
Unknown or Not Reported0000
08

Study locations

1 site
  • Ehime Medical Center
    Ehime, 791-0281, Japan
09

References and documents

Publications

  • Wada Y, Jensen C, Meyer ASP, Zonoozi AAM, Honda H. Efficacy and safety of interleukin-6 inhibition with ziltivekimab in patients at high risk of atherosclerotic events in Japan (RESCUE-2): A randomized, double-blind, placebo-controlled, phase 2 trial. J Cardiol. 2023 Oct;82(4):279-285. doi: 10.1016/j.jjcc.2023.05.006. Epub 2023 May 19. PubMed 37211246 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2020 to primary completion in Aug 2021, 9 months.

Results were first posted in May 2026, 4 years 9 months after primary completion.

Of 80 industry-sponsored phase 2 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 31. This study's 9 months is below that.

Counting every sponsor, half of 139 studies reached it within 25 months; a quarter within 15 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2020
First posted
Nov 12, 2020
StartActual
Oct 22, 2020
Primary completionActual
Aug 3, 2021
CompletionActual
Sep 28, 2021
Results first posted
May 6, 2026
Last update
May 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04626505
Lead sponsor
Novo Nordisk A/S
Collaborators
Corvidia Therapeutics
Responsible party
Sponsor
First posted
Nov 12, 2020
Start date
Oct 22, 2020
Primary completion
Aug 3, 2021
Completion
Sep 28, 2021
Results posted
May 6, 2026
Last update
May 6, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ziltivekimab

Start the discussion